- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03165838
Effectiveness of Shortened Time Interval to Postpartum Visit in Improving Postpartum Attendance
Studieoversigt
Status
Intervention / Behandling
Detaljeret beskrivelse
Postpartum care is an essential component of women's reproductive health. During this time, the health care provider and the new mother review the previous pregnancy course, assess the mother's wellbeing, and establish treatment plans for any ongoing problems. Prospective guidance is given for both the mother and the baby in areas such as breastfeeding, nutrition, depression screening, and perineal/vulvar care. However, one of the most important goals of the postpartum visit is to discuss the new mother's desire for future pregnancies and the interval she wishes before another pregnancy. Inadequate reproductive health planning may result in unintended or rapid repeat of pregnancy (RROP), clinically defined as a second pregnancy within 24 months of the end of a previous pregnancy. A short inter-pregnancy interval is a risk factor for poor pregnancy outcomes including stillbirth, early neonatal death, extreme preterm births, and babies born small for gestational age. Compared to women who conceived 18-23 months after a previous birth, women conceiving less than five months after a previous birth had increased third trimester bleeding, uterine infection, premature rupture of membranes, and maternal death.Central to these outcomes is the rate of postpartum contraception use.
In fact, research shows an association between a postpartum visit and use of a reliable contraceptive method after pregnancy.
The optimal time for postpartum visit may be 3-4 weeks post-delivery rather than 6-8 weeks post-delivery with regard to visit attendance and proactive management of reproductive health, including contraception and time intervals between pregnancies. The timing of the postpartum visits are also linked to economic outcomes and healthcare utilization; postpartum care that results in decreased RROP and unintended pregnancies will likely decrease healthcare costs associated with the adverse consequences of inadequate reproductive health planning. Despite the obvious potential benefits of a decreased interval between delivery and the postpartum visit, to date, there have been no studies to systematically compare the impact of postpartum visit timing on visit attendance, contraception use and, subsequently, RROP.
This study is designed to investigate the effect of reduced time interval to postpartum visit on postpartum visit attendance rate, contraceptive use, and RROP. Additionally, the study will assess the impact of the two visit schedules on these outcomes by race, providing critical information about high risk populations. Finally, this research will assess the cost effectiveness of the shortened postpartum visit schedule relative to the standard of care. In order to account for potential bias in increased attendance rate due to intervention effect, compensation and other factors, this study will also compare the effectiveness of shortened time interval to postpartum visit on postpartum attendance rate and contraceptive use to a historic cohort.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- at least 18 years of age
- delivered vaginally a healthy, full-term (at least 37 weeks gestation) baby
- received prenatal care services at the VCUMCV OB clinic
- speak English
- provide informed consent for study participation.
Exclusion Criteria:
- cognitive impairment, psychiatric instability, or language barriers that limit their ability to provide informed consent
- surgically sterilized
- have complicated deliveries that require extended hospital stays
- need early follow-up to monitor their conditions
- any problems with infants such as preterm birth, admission to the Neonatal Intensive Care Unit (NICU), congenital malformations or respiratory problems that would require frequent clinic visits or prolonged hospital admissions for the infants.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Postpartum Visit 3-4 Weeks
Participants will have postpartum visit scheduled 3-4 weeks after birth
|
This visit will be the same as the standard of care postpartum visit, but it will be scheduled earlier.
|
|
Eksperimentel: Postpartum Visit 6-8 Weeks
Participants will have postpartum visit scheduled 6-8 weeks after birth
|
This standard of care postpartum visit will be scheduled for the standard time interval.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Postpartum Clinic Attendance
Tidsramme: assessed at 12 weeks postpartum
|
To compare the effectiveness of 3-4 week and 6-8 week intervals to postpartum visit on improving the rate of postpartum visit attendance.
The investigators hypothesize that study participants with postpartum visits scheduled 3-4 weeks after delivery will be more likely to attend visits than study participants scheduled for visits 6-8 weeks after delivery.
|
assessed at 12 weeks postpartum
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Contraception Use
Tidsramme: Assessed at 3, 6, 9, 12, & 18 month follow-ups
|
Compare the effectiveness of 3-4 week and 6-8 week intervals to postpartum visit on consistent contraceptive use
|
Assessed at 3, 6, 9, 12, & 18 month follow-ups
|
|
Rapid Repeat Pregnancy
Tidsramme: Assessed at 3, 6, 9, 12, & 18 month follow-ups
|
Compare the effectiveness of 3-4 week and 6-8 week intervals to postpartum visit on repeat pregnancy
|
Assessed at 3, 6, 9, 12, & 18 month follow-ups
|
|
Cost effectiveness
Tidsramme: 18 month postpartum
|
Compare overall cost of postpartum care
|
18 month postpartum
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Racial Differences
Tidsramme: baseline, postpartum, 3, 6, 9, 12, & 18 month follow-ups
|
Compare the effectiveness of 3-4 week and 6-8 week intervals to postpartum visit on reducing racial differences in postpartum visit attendance rates and contraceptive use.
Specifically, the study team hypothesizes that the difference in postpartum visit attendance and consistent contraceptive use rates between AA and CA study participants will be lower among study participants with postpartum visits scheduled 3-4 weeks after delivery compared to study participants scheduled for visits 6-8 weeks after delivery.
|
baseline, postpartum, 3, 6, 9, 12, & 18 month follow-ups
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Saba W Masho, Virginia Commonwealth University
Publikationer og nyttige links
Generelle publikationer
- Yonemoto N, Nagai S, Mori R. Schedules for home visits in the early postpartum period. Cochrane Database Syst Rev. 2021 Jul 21;7(7):CD009326. doi: 10.1002/14651858.CD009326.pub4.
- Masho SW, Ihongbe TO, Wan W, Graves WC, Karjane N, Dillon P, Bazzoli G, McGee E. Effectiveness of shortened time interval to postpartum visit in improving postpartum attendance: Design and rationale for a randomized controlled trial. Contemp Clin Trials. 2019 Jun;81:40-43. doi: 10.1016/j.cct.2019.04.012. Epub 2019 Apr 18.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
- HM20000032
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Graviditetsrelateret
-
University Hospital, Clermont-FerrandAfsluttetOral Health Related Quality of Life (OHRQoL)Frankrig
-
Riyadh Elm UniversityAfsluttetOral Health Related Quality of Life OHRQoLSaudi Arabien
-
University of MalayaUkendtTranspalatal bue (TPA) | Oral Health Related Quality of Life (OHRQoL) | Oral Health Impact Profile Short Version 14 (OHIP 14) | Ortodontiske smerter | Tredimensionel (3D) ortodontisk enhedMalaysia
-
University of MilanAssociazione Italiana Mowat Wilson (Mowat Wilson Italian Association)Ikke rekrutterer endnuPeriodontale sygdomme | Caries i tænderne | Tandsygdomme | Maloklusion | Kraniofaciale abnormiteter | Tandabnormiteter | Oral slimhindesygdom | Oral Health Related Quality of Life (OHRQoL) | Søvnrelateret vejrtrækningsforstyrrelse | Mowat-Wilson SyndromItalien
-
King's College Hospital NHS TrustEuropean Association for the Study of the LiverRekrutteringCirrhose, lever | HELLP syndrom | Intrahepatisk kolestase af graviditet | Graviditetssygdom | AFLP - Acute Fatty Lever of PregnancyDet Forenede Kongerige
-
National Human Genome Research Institute (NHGRI)Children's National Research Institute; Uniformed Services University of...RekrutteringProteus syndrom | PIK3CA Related Overgrowth SpectrumForenede Stater
Kliniske forsøg med Postpartum Visit 3-4 Weeks
-
Ohio State UniversityRekrutteringGraviditet, høj risiko | Svangerskabsdiabetes | Præ-graviditetsdiabetes | Graviditet hos diabetikere | Type 2 diabetes | Svangerskabsdiabetes mellitus i PuerperiumForenede Stater
-
Jeffrey A. Cohen, MDJacobus PharmaceuticalAfsluttetMuskelsvaghedForenede Stater
-
Madigan Army Medical CenterAfsluttetLivmoderhalskræft | Fødselsdepression | Graviditet | Svangerskabsforebyggelse | AmningForenede Stater
-
Hospital Central Norte PEMEXAfsluttetUdførelse af koloskopi | Tolerance af koloskopiMexico
-
Pharma Holdings ASCTC Clinical Trial Consultants ABAfsluttetNasal afkolonisering af Staphylococcus AureusSverige
-
Seoul National University HospitalUkendt
-
Merz Pharmaceuticals GmbHAfsluttetKorrektion af ansigtsrynker/folder | Forbedring af ansigtsvolumenTyskland
-
IpsenAktiv, ikke rekrutterendePrimær biliær kolangitisJapan
-
AccSalus Biosciences, Inc.Ikke rekrutterer endnuMelanom | Nyrecellekarcinom | Hepatocellulært karcinom | Gastrisk Adenocarcinom | Avanceret solid tumor | Gastroøsofageal Junction Adenocarcinom | Galdeblærekræft | Skjoldbruskkirtelcarcinom, medullært | Primær differentieret Tyreoidea Carcinom
-
REDNVIA Co., Ltd.SuspenderetCalcific aortaklapsygdomForenede Stater, Canada